CN115335066A - 经工程化以治疗其中草酸盐有害的病症的细菌 - Google Patents

经工程化以治疗其中草酸盐有害的病症的细菌 Download PDF

Info

Publication number
CN115335066A
CN115335066A CN202180020940.5A CN202180020940A CN115335066A CN 115335066 A CN115335066 A CN 115335066A CN 202180020940 A CN202180020940 A CN 202180020940A CN 115335066 A CN115335066 A CN 115335066A
Authority
CN
China
Prior art keywords
oxalate
gene
encoding
promoter
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180020940.5A
Other languages
English (en)
Chinese (zh)
Inventor
V·M·伊莎贝拉
D·卢伯克维茨
M·詹姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synchronic Operation Co
Original Assignee
Synchronic Operation Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synchronic Operation Co filed Critical Synchronic Operation Co
Publication of CN115335066A publication Critical patent/CN115335066A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/03—CoA-transferases (2.8.3)
    • C12Y208/03016—Formyl-CoA transferase (2.8.3.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01002—Oxalate decarboxylase (4.1.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01008—Oxalyl-CoA decarboxylase (4.1.1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
    • C12Y602/01—Acid-Thiol Ligases (6.2.1)
    • C12Y602/01008—Oxalate--CoA ligase (6.2.1.8)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180020940.5A 2020-01-14 2021-01-14 经工程化以治疗其中草酸盐有害的病症的细菌 Pending CN115335066A (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202062960950P 2020-01-14 2020-01-14
US62/960,950 2020-01-14
US202062993301P 2020-03-23 2020-03-23
US62/993,301 2020-03-23
US202063028902P 2020-05-22 2020-05-22
US63/028,902 2020-05-22
US202063065752P 2020-08-14 2020-08-14
US63/065,752 2020-08-14
US202063089758P 2020-10-09 2020-10-09
US63/089,758 2020-10-09
US202063091620P 2020-10-14 2020-10-14
US63/091,620 2020-10-14
US202063111376P 2020-11-09 2020-11-09
US63/111,376 2020-11-09
PCT/US2021/013401 WO2021146397A1 (en) 2020-01-14 2021-01-14 Bacteria engineered to treat disorders in which oxalate is detrimental

Publications (1)

Publication Number Publication Date
CN115335066A true CN115335066A (zh) 2022-11-11

Family

ID=76864711

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180020940.5A Pending CN115335066A (zh) 2020-01-14 2021-01-14 经工程化以治疗其中草酸盐有害的病症的细菌

Country Status (9)

Country Link
US (1) US20230092431A1 (https=)
EP (1) EP4090343A4 (https=)
JP (1) JP2023511282A (https=)
CN (1) CN115335066A (https=)
AU (1) AU2021207879A1 (https=)
BR (1) BR112022013867A2 (https=)
CA (1) CA3167754A1 (https=)
IL (1) IL294710A (https=)
WO (1) WO2021146397A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
WO2022204406A1 (en) * 2021-03-24 2022-09-29 Synlogic Operating Company, Inc. Bacteria engineered to treat disorders in which oxalate is detrimental
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
GB202402011D0 (en) 2024-02-14 2024-03-27 Snipr Biome Aps A novel type of crispr/cas system
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1365284A (zh) * 1999-05-28 2002-08-21 Vsl制药有限公司 用于预防或治疗尿草酸盐过多的膳食或药物组合物
US20180325963A1 (en) * 2015-08-31 2018-11-15 Synlogic, Inc. Bacteria engineered to treat disorders in which oxalate is detrimental
WO2018237198A1 (en) * 2017-06-21 2018-12-27 Synlogic Operating Company, Inc. BACTERIA FOR THE TREATMENT OF DISORDERS
CN109641019A (zh) * 2016-06-13 2019-04-16 奥克斯泰拉知识产权公司 用于治疗或预防草酸盐相关病症的组合物和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070052A2 (en) * 2005-12-14 2007-06-21 Oxthera, Inc. Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
US9283252B2 (en) * 2008-09-30 2016-03-15 Meiji Co., Ltd. Lactic acid bacterium having high oxalic acid decomposition ability
JP2020527025A (ja) * 2017-07-12 2020-09-03 シンロジック オペレーティング カンパニー インコーポレイテッド 腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物
IT201800005355A1 (it) * 2018-05-14 2019-11-14 Lactobacillus amylovorus SGL 14: attività probiotiche e riduzione dell’ossalato enterico

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1365284A (zh) * 1999-05-28 2002-08-21 Vsl制药有限公司 用于预防或治疗尿草酸盐过多的膳食或药物组合物
US20180325963A1 (en) * 2015-08-31 2018-11-15 Synlogic, Inc. Bacteria engineered to treat disorders in which oxalate is detrimental
CN109641019A (zh) * 2016-06-13 2019-04-16 奥克斯泰拉知识产权公司 用于治疗或预防草酸盐相关病症的组合物和方法
WO2018237198A1 (en) * 2017-06-21 2018-12-27 Synlogic Operating Company, Inc. BACTERIA FOR THE TREATMENT OF DISORDERS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUNHYE LEE 等: ""Expression of the gene encoding oxalate decarboxylase from Bacillus subtilis and characterization of the recombinant enzyme"", 《BMC RES NOTES》, vol. 7, no. 598, 3 September 2014 (2014-09-03) *
张帝 等: ""益生菌治疗草酸钙结石的研究进展"", 《解放军医学杂志》, no. 08, 1 August 2016 (2016-08-01), pages 90 - 94 *

Also Published As

Publication number Publication date
BR112022013867A2 (pt) 2022-09-13
WO2021146397A1 (en) 2021-07-22
EP4090343A4 (en) 2024-02-14
JP2023511282A (ja) 2023-03-17
US20230092431A1 (en) 2023-03-23
AU2021207879A1 (en) 2022-09-08
IL294710A (en) 2022-09-01
CA3167754A1 (en) 2021-07-22
EP4090343A1 (en) 2022-11-23

Similar Documents

Publication Publication Date Title
US12545886B2 (en) Bacteria for the treatment of disorders
US20220233609A1 (en) Bacteria engineered to treat disorders in which oxalate is detrimental
JP7245271B2 (ja) 高フェニルアラニン血症を低減させるように操作された細菌
JP7494345B2 (ja) 高フェニルアラニン血症を低減させるように操作された細菌
CN115335066A (zh) 经工程化以治疗其中草酸盐有害的病症的细菌
CN107636146A (zh) 被工程化为治疗受益于降低的消化道炎症和/或收紧的消化道粘膜屏障的疾病的细菌
JP2018535678A5 (https=)
WO2017123592A1 (en) Bacteria engineered to treat disorders associated with bile salts
EP3328988A1 (en) Bacteria engineered to treat disorders involving propionate catabolism
US20240197843A1 (en) Bacteria engineered to treat disorders in which oxalate is detrimental
WO2024129974A1 (en) Recombinant bacteria for use in the treatment of disorders in which oxalate is detrimental
WO2024081768A1 (en) Bacteria engineered to produce active epidermal growth factor (egf) and their medical uses
CN117083068A (zh) 经工程化以治疗其中草酸盐有害的病症的细菌
EP4543470A1 (en) Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination